ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

RXDX Prometheus Biosciences Inc

199.92
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Prometheus Biosciences Inc NASDAQ:RXDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 199.92 194.00 199.90 0 01:00:00

Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

14/05/2021 9:01pm

GlobeNewswire Inc.


Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Prometheus Biosciences Charts.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.

A live and archived webcast of the virtual fireside chat will be available via the Events section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD. The Company’s precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.  Prometheus is headquartered in San Diego, CA.

Contacts:Noel KurdiVP Investor Relations and Communications(646) 241-4400nkurdi@prometheusbiosciences.com 

Media contact:Juniper PointAmy Conrad(858) 914-1962media@prometheusbiosciences.com 

1 Year Prometheus Biosciences Chart

1 Year Prometheus Biosciences Chart

1 Month Prometheus Biosciences Chart

1 Month Prometheus Biosciences Chart

Your Recent History

Delayed Upgrade Clock